MedTrace Logo

Prostate Cancer Screening Among Men With High Risk Genetic Predisposition

NCT02053805 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2017-10-17

No results posted yet for this study

Summary

This will be a prospective diagnostic trial of screening for prostate cancer among men with genetic predisposition.

Conditions

Interventions

OTHER

PSA

PSA. Serum \& plasma will be stored for future investigations

OTHER

IPSS questionnaire

the validated International Prostate Symptom Score

OTHER

DRE (Digital Rectal Examination )

physical examination for the prostate gland

OTHER

urine flow and residual

The post void residual will be recorded by using ultrasound. Creatinine level will be checked.

PROCEDURE

a multiparametric prostate MRI

The MRI will be reported on a 5 point Likert Scale

PROCEDURE

trans-rectal ultra-sound guided prostate biopsy

12 core Trans-rectal prostatic biopsy for diagnostic purposes

Sponsors & Collaborators

  • Rabin Medical Center

    lead OTHER

Principal Investigators

  • David Margel, MD PhD · Rabn Medical Center, Beilinson Campus

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2018-06-30
Completion
2019-06-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02053805 on ClinicalTrials.gov